Statin in Hip Fracture

Efficacy and Safety of Rosuvastatin in the Prevention of Arterial and Venous Vascular Events and Mortality After Hip Fracture: A Multicenter Randomised, Double-blinded, Placebo Controlled Trial.

Status

Terminated

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01494090

Acronym

STAFF

Enrollment

Registered

2011-12-16

Start date

2011-08-31

Completion date

2012-09-30

Last updated

2012-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip Fracture

Keywords

Venous thromboembolism, Hip fracture, Cardiovascular events, Statin

Brief summary

Statins (or HMG-CoA reductase inhibitors) have largely proven their efficacy in the primary and secondary prevention of cardiovascular events. Many clinical and experimental studies support also a potential beneficial effect of statin therapy on venous thromboembolism (VTE). Patients with hip fracture are at high risk of VTE and cardiovascular events. The aim of this study is to evaluate the efficacy and the tolerance of a statin (rosuvastatin) in hip fracture surgery on the occurrence of venous and atherothrombotic events and the global mortality at six months. Subjects aged 60 years or over who are scheduled to undergo surgery for fracture of the upper portion of the femur (hip fracture) are eligible to participate to this multicentre, randomized, double-blind placebo controlled trial. They will receive either rosuvastatin (5 or 20 mg) or placebo for 6 months. The primary efficacy outcome is the incidence of an adjudicated composite of non fatal VTE, acute coronary syndrome, non fatal stroke, other acute ischemic arterial event, or all-cause death. Assuming a endpoint frequency of 20% in the control group, we calculated that 1200 patients will be required for the study to have 80% power to detect a 30% reduction in the relative risk with rosuvastatin (with a two-sided alpha level of 5%). The investigators assumed that rosuvastatin could have a positive benefit-risk ratio in patients undergoing orthopaedic surgery for hip fracture, by reducing vascular events and global mortality at six months.

Interventions

DRUGRosuvastatin

5 or 20 mg per day during 6 months

DRUGPlacebo

5 or 20 mg per day during 6 months

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

60 Years to No maximum

Healthy volunteers

Inclusion criteria

* 60 years old or older. * fracture of the femoral neck or of the trochanteric mass * undergoing surgery within 5 days for this fracture * Signed written informed consent

Exclusion criteria

* contraindication to rosuvastatin: * active liver disease including unexplained and prolonged elevations of serum transaminases and any increase of serum transaminases beyond 3 times the upper limit of normal * severe renal impairment (creatinine clearance calculated by the formula MDRD \<30 ml / min) * myopathy * use of cyclosporine * statin therapy ongoing at the admission for fracture * curative anticoagulant therapy ongoing at the admission and expected to be maintained after the intervention * Patients considered by the investigator to be unable to participate to the study * Refuse to participate

Design outcomes

Primary

Measure	Time frame	Description
Occurence of Arterial and Venous Vascular Events and Mortality	6 months	* Nonfatal symptomatic thromboembolic venous desease * Acute coronary syndrome * Nonfatal ischemic stroke or transient ischemic attack * Acute peripheral arterial ischemia * Deaths from all causes

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026